Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Chen, L Siveke, J Wang-Gillam, A Hubner, Richard A Pant, S Dragovich, T Chung, V Chang, D Ross, P Cooray, P
Chen, L
Siveke, J
Wang-Gillam, A
Hubner, Richard A
Pant, S
Dragovich, T
Chung, V
Chang, D
Ross, P
Cooray, P
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. 2016, 27:110-110 Ann Oncol